- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00019656
Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic Cancer
A Phase I Trial of Oral Perifosine With Different Loading Schedules in Patients With Refractory Neoplasms
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase I trial to study the effectiveness of perifosine in treating patients who have refractory solid tumors or hematologic cancer.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
OBJECTIVES:
- Determine the dose-limiting toxicity and maximum tolerated dose of perifosine administered as a varying series of loading and maintenance doses in patients with refractory solid tumors, non-Hodgkin's lymphoma, chronic lymphocytic leukemia, myelodysplastic syndromes, or Hodgkin's lymphoma.
- Determine the profile of adverse reactions (including changes in laboratory parameters) in patients treated with this regimen.
- Determine any disease responses that may occur in patients treated with this regimen.
- Determine the steady-state pharmacology and pharmacokinetics of this regimen in these patients.
OUTLINE: This is a dose-escalation study.
Patients receive a loading dose of oral perifosine on day 1 followed by a maintenance dose 2-3 times daily beginning on day 2 or 3 and continuing until day 21. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.
Cohorts of 3-6 patients receive escalating loading and maintenance doses of perifosine until the maximum tolerated dose (MTD) of each is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, an additional 10 patients are treated at that dose level.
Patients are followed every 3 months.
PROJECTED ACCRUAL: A maximum of 45 patients will be accrued for this study within 12-18 months.
Studietyp
Fas
- Fas 1
Kontakter och platser
Studieorter
-
-
Maryland
-
Bethesda, Maryland, Förenta staterna, 20892-1182
- Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support
-
Bethesda, Maryland, Förenta staterna, 20892
- NCI - Center for Cancer Research
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
DISEASE CHARACTERISTICS:
- Histologically confirmed solid tumor, non-Hodgkin's lymphoma, chronic lymphocytic leukemia, myelodysplastic syndromes, or Hodgkin's lymphoma that has no effective standard therapeutic option but requires systemic therapy
- No history of CNS neoplasms
For prostate cancer:
- Tumor progression during blockade of testicular and adrenal androgens
- At least 4 weeks since prior flutamide or other antiandrogens without disease improvement
- Leuprolide or other gonadotropin-releasing hormones should be maintained in patients without an orchiectomy
- Testosterone in the castrate range
For breast cancer:
- At least 4 weeks since any prior hormonal therapy with evidence of disease progression
PATIENT CHARACTERISTICS:
Age:
- Over 18
Performance status:
- ECOG 0-2
Life expectancy:
- Not specified
Hematopoietic:
- Platelet count greater than 50,000/mm^3
- Absolute granulocyte count greater than 500/mm^3
- Hemoglobin at least 9.0 g/dL
Hepatic:
- Bilirubin no greater than 1.5 mg/dL
- SGOT and SGPT no greater than 2.5 times normal
Renal:
- Creatinine no greater than 1.5 mg/dL OR
- Creatinine clearance at least 60 mL/min
Cardiovascular:
- No history of unstable or newly diagnosed angina pectoris
- No myocardial infarction within the past 6 months
- No New York Heart Association class II-IV heart disease
Other:
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- HIV negative
- No recent acute or chronic gastrointestinal conditions (e.g., stomach ulcer or enteritis) that might affect tolerability or drug absorption
- No allergic reaction to any medication with a structure similar to perifosine
- No pre-existing retinal disease or pathologic baseline electrooculogram
- No cataracts that would interfere with normal vision or require medical intervention
- No other serious concurrent illness that would preclude assessment of drug effect
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- Not specified
Chemotherapy:
- At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered
- At least 2 months since prior UCN-01
- More than 3 months since prior suramin
Endocrine therapy:
- See Disease Characteristics
- No concurrent corticosteroids except for physiological replacement or as antiemetics
Radiotherapy:
- At least 4 weeks since prior radiotherapy (6 weeks for bone-seeking radioisotopes) and recovered
Surgery:
- See Disease Characteristics
Other:
- No other concurrent antineoplastic therapies
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
Samarbetspartners och utredare
Sponsor
Utredare
- Studiestol: Edward A. Sausville, MD, PhD, National Cancer Institute (NCI)
Publikationer och användbara länkar
Allmänna publikationer
- Monga M, Messmann RA, Headlee D, et al.: A phase I trial of oral perifosine in patients with refractory neoplasms. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-1837, 7b, 2002.
- Messmann RA, Headlee D, Woo EW, et al.: A phase I trial of oral perifosine with different loading and maintenance schedules in patients with refractory neoplasms. [Abstract] Proc Am Assoc Cancer Res 42: A-2880, 2001.
Studieavstämningsdatum
Studera stora datum
Studiestart
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
- ospecificerad vuxen solid tumör, protokollspecifik
- stadium IV grad 3 follikulärt lymfom
- stadium IV vuxen diffust storcelligt lymfom
- stadium IV vuxen immunoblastiskt storcelligt lymfom
- stadium IV vuxen Burkitt lymfom
- återkommande follikulärt lymfom grad 3
- återkommande vuxen diffust storcelligt lymfom
- återkommande vuxen immunoblastiskt storcelligt lymfom
- återkommande vuxen Burkitt lymfom
- kronisk myelomonocytisk leukemi
- de novo myelodysplastiska syndrom
- tidigare behandlade myelodysplastiska syndrom
- sekundära myelodysplastiska syndrom
- återkommande vuxen Hodgkin-lymfom
- återkommande vuxen diffusa små kluvna lymfom
- återkommande diffust blandat celllymfom hos vuxna
- stadium IV grad 1 follikulärt lymfom
- stadium IV grad 2 follikulärt lymfom
- stadium IV vuxen diffust småklyvt lymfom
- stadium IV diffust blandat celllymfom hos vuxna
- stadium IV mantelcellslymfom
- återkommande follikulärt lymfom grad 1
- återkommande follikulärt lymfom grad 2
- återkommande lymfom i marginalzonen
- återkommande små lymfocytiska lymfom
- stadium IV små lymfocytiska lymfom
- stadium IV marginalzon lymfom
- extranodal marginalzon B-cellslymfom i slemhinneassocierad lymfoid vävnad
- nodal marginalzon B-cells lymfom
- marginalzonens lymfom i mjälten
- återkommande lymfoblastiskt lymfom hos vuxna
- återkommande mantelcellslymfom
- refraktär kronisk lymfatisk leukemi
- stadium IV kronisk lymfatisk leukemi
- stadium IV vuxen Hodgkin lymfom
- stadium IV vuxen lymfoblastiskt lymfom
- myelodysplastisk/myeloproliferativ neoplasm, oklassificerbar
- atypisk kronisk myeloid leukemi, BCR-ABL1 negativ
Ytterligare relevanta MeSH-villkor
- Patologiska processer
- Immunsystemets sjukdomar
- Neoplasmer efter histologisk typ
- Lymfoproliferativa störningar
- Lymfatiska sjukdomar
- Immunproliferativa störningar
- Sjukdom
- Benmärgssjukdomar
- Hematologiska sjukdomar
- Precancerösa tillstånd
- Neoplasmer
- Lymfom
- Syndrom
- Myelodysplastiska syndrom
- Leukemi
- Preleukemi
- Myeloproliferativa störningar
- Myelodysplastiska-myeloproliferativa sjukdomar
Andra studie-ID-nummer
- CDR0000066960
- NCI-99-C-0043
- NCI-T98-0065
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .